Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Immunocore Holdings plc
IMCR
$33.99
Name : Immunocore Holdings plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,712,656,512.00
EPSttm : -0.41
finviz dynamic chart for IMCR
Immunocore Holdings plc
$33.99
0.67%
$0.23

Float Short %

17.39

Margin Of Safety %

-19

Put/Call OI Ratio

5.1

EPS Next Q Diff

-0.12

EPS Last/This Y

0.36

EPS This/Next Y

-0.58

Price

33.99

Target Price

62.68

Analyst Recom

1.67

Performance Q

-4.12

Relative Volume

1.04

Beta

0.8

Ticker: IMCR




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-09IMCR36.575.060.0021042
2025-09-10IMCR36.465.060.0021042
2025-09-11IMCR36.575.060.0021042
2025-09-12IMCR35.215.060.0021042
2025-09-15IMCR34.415.06999.9921043
2025-09-16IMCR33.845.070.0021094
2025-09-17IMCR33.425.0513188073394021107
2025-09-18IMCR33.415.044.6721112
2025-09-19IMCR32.515.040.0021115
2025-09-22IMCR33.325.09999.9921079
2025-09-23IMCR34.865.120.0021179
2025-09-24IMCR34.715.120.0021180
2025-09-25IMCR34.15.120.0021180
2025-09-26IMCR34.065.120.0021182
2025-09-29IMCR34.415.120.0021182
2025-09-30IMCR36.295.110.0021187
2025-10-01IMCR35.865.110.0021188
2025-10-02IMCR35.125.110.0021188
2025-10-03IMCR34.235.10999.9921196
2025-10-06IMCR34.035.103.0021199
2025-10-07IMCR34.665.103.0021199
2025-10-08IMCR33.935.101.0021203
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-09IMCR36.58-251.6-145.3-0.67
2025-09-10IMCR36.44-251.6-144.8-0.67
2025-09-11IMCR36.57-251.6-146.6-0.67
2025-09-12IMCR35.21-251.6-138.3-0.67
2025-09-15IMCR34.42-251.6-140.6-0.67
2025-09-16IMCR33.81-251.6-142.1-0.67
2025-09-17IMCR33.38-251.6-143.2-0.67
2025-09-18IMCR33.53-251.6-146.7-0.67
2025-09-19IMCR32.56-251.6-140.6-0.67
2025-09-22IMCR33.25-249.6-150.0-0.66
2025-09-23IMCR34.41-249.6-153.1-0.66
2025-09-24IMCR34.21-249.6-144.7-0.66
2025-09-25IMCR34.08-249.6-144.8-0.66
2025-09-26IMCR34.02-249.6-145.6-0.66
2025-09-29IMCR34.41-249.6-148.3-0.66
2025-09-30IMCR36.28-249.6-157.4-0.66
2025-10-01IMCR35.91-249.6-143.5-0.66
2025-10-02IMCR35.21-249.6-141.8-0.66
2025-10-03IMCR34.21-249.6-139.6-0.66
2025-10-06IMCR34.06-249.6-138.7-0.66
2025-10-07IMCR34.28-249.6-147.4-0.66
2025-10-08IMCR33.99-249.6-144.4-0.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-09IMCR210.908.2417.63
2025-09-10IMCR210.908.2417.63
2025-09-11IMCR210.908.2417.46
2025-09-12IMCR197.738.2417.46
2025-09-15IMCR197.737.5117.46
2025-09-16IMCR191.797.5117.46
2025-09-17IMCR191.797.5117.46
2025-09-18IMCR191.797.5117.46
2025-09-19IMCR191.797.5117.46
2025-09-22IMCR-16.047.5017.46
2025-09-23IMCR-16.047.5017.46
2025-09-24IMCR-16.047.5017.46
2025-09-25IMCR-16.047.5017.39
2025-09-26IMCR-16.047.5017.39
2025-09-29IMCR-16.047.4617.39
2025-09-30IMCR-16.047.4617.39
2025-10-01IMCR-16.047.4617.39
2025-10-02IMCR-16.047.4617.39
2025-10-03IMCR-26.077.4617.39
2025-10-06IMCR-26.075.7017.39
2025-10-07IMCR-26.075.7017.39
2025-10-08IMCR-26.075.7017.39
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.2

Avg. EPS Est. Current Quarter

-0.25

Avg. EPS Est. Next Quarter

-0.32

Insider Transactions

-26.07

Institutional Transactions

5.7

Beta

0.8

Average Sales Estimate Current Quarter

101

Average Sales Estimate Next Quarter

105

Fair Value

27.6

Quality Score

52

Growth Score

56

Sentiment Score

4

Actual DrawDown %

55.9

Max Drawdown 5-Year %

Target Price

62.68

P/E

Forward P/E

PEG

P/S

4.79

P/B

4.43

P/Free Cash Flow

59.72

EPS

-0.41

Average EPS Est. Cur. Y​

-0.66

EPS Next Y. (Est.)

-1.24

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-5.62

Relative Volume

1.04

Return on Equity vs Sector %

-30.4

Return on Equity vs Industry %

-16.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-144.4
Immunocore Holdings plc
Sector: Healthcare
Industry: Biotechnology
Employees: 493
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
stock quote shares IMCR – Immunocore Holdings plc ADR Stock Price stock today
news today IMCR – Immunocore Holdings plc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMCR – Immunocore Holdings plc ADR yahoo finance google finance
stock history IMCR – Immunocore Holdings plc ADR invest stock market
stock prices IMCR premarket after hours
ticker IMCR fair value insiders trading